• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Pediatric Vaccines Market

    ID: MRFR/Pharma/4323-HCR
    95 Pages
    Rahul Gotadki
    September 2025

    Pediatric Vaccines Market Research Report By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Conjugate Vaccines), By Administration Route (Intramuscular, Subcutaneous, Oral, Nasal), By Age Group (Infants, Children, Adolescents), By Disease Target (Viral Infections, Bacterial Infections, Parasitic Infections) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2034

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Pediatric Vaccines Market Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Pediatric Vaccines Market Summary

    The Global Pediatric Vaccines Market is projected to grow significantly from 19.2 USD Billion in 2024 to 54.2 USD Billion by 2035.

    Key Market Trends & Highlights

    Pediatric Vaccines Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 9.9 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 54.2 USD Billion, indicating robust growth.
    • In 2024, the market is valued at 19.2 USD Billion, reflecting a strong foundation for future expansion.
    • Growing adoption of innovative vaccine technologies due to increasing awareness of preventive healthcare is a major market driver.

    Market Size & Forecast

    2024 Market Size 19.2 (USD Billion)
    2035 Market Size 54.2 (USD Billion)
    CAGR (2025-2035) 9.9%

    Major Players

    BristolMyers Squibb, Sanofi, Emergent BioSolutions, HoffmannLa Roche, United Therapeutics, AbbVie, VBI Vaccines, Serum Institute of India, GlaxoSmithKline, Johnson and Johnson, Valneva, Pfizer, Inovio Pharmaceuticals, Merck and Co, Novartis

    Pediatric Vaccines Market Trends

    The Pediatric Vaccines Market is currently in transition as more people understand the relevance of vaccination and the number of children suffering from vaccine-preventable diseases increases. The continuous attempts by governments and health agencies to promote inoculation programs, as well as the developments in vaccination technology, provide a good background for the growth of the market. 

    In addition, the recent worldwide health issues have highlighted the importance of vaccination as a prime strategy, thereby enhancing the focus on vaccine manufacturing and distribution. This market has potential owing to the growing need for multivalent vaccines that offer multi-disease protection with a single administration of the vaccine.

    The movement facilitates the immunization of parents and healthcare providers while maximizing vaccination coverage. Moreover, the focus on engaging ongoing r&d in mRNA and other vaccine platforms brings them a step closer to making great transparent breakthroughs in margins of safety and efficacy. Untapped growth is also afforded by children’s healthcare initiatives in regions with lower vaccination rates. 

    Recent examples have shown heightened interest in improving vaccine access in poorer regions, including among initiatives from the public and private sectors. The development of telemedicine consultations has also enhanced the tracking and management of vaccination schedules, easing the strain on families to keep their children up to date with vaccinations.

    In addition, there is an increase in collaboration in the vaccine supply chain between pharmaceutical companies and public health bodies to enhance vaccine distribution and funding and educational programs targeting parents to increase the uptake of vaccines. Polio's dominant picture is one that is focused on a practical cause- that of preventing children from missing important vaccines, hence improving the health of future generations of populations across the globe.

    The increasing emphasis on immunization programs globally suggests a robust trajectory for the pediatric vaccines market, driven by heightened awareness of vaccine-preventable diseases and the need for comprehensive healthcare strategies.

    World Health Organization (WHO)

    Pediatric Vaccines Market Drivers

    Market Growth Projections

    The Global Pediatric Vaccines Market Industry is poised for robust growth, with projections indicating a market value of 19.2 USD Billion in 2024 and an anticipated increase to 54.2 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 9.9% from 2025 to 2035. Such figures reflect the increasing recognition of the importance of vaccination in public health and the ongoing efforts to improve vaccine access and coverage globally. The market's expansion is likely to be driven by a combination of factors, including rising disease incidence, government initiatives, and technological advancements.

    Government Initiatives and Funding

    Government initiatives play a crucial role in shaping the Global Pediatric Vaccines Market Industry. Many countries are implementing national immunization programs that provide free or subsidized vaccines to children. For example, the Global Alliance for Vaccines and Immunization (GAVI) collaborates with governments to enhance vaccine access in developing nations. Such initiatives not only increase vaccination coverage but also stimulate market growth by ensuring a steady demand for pediatric vaccines. As funding for immunization programs continues to rise, the market is expected to expand significantly, with projections indicating a value of 54.2 USD Billion by 2035.

    Emerging Markets and Population Growth

    Emerging markets are becoming increasingly important in the Global Pediatric Vaccines Market Industry. Countries in Asia, Africa, and Latin America are experiencing rapid population growth, leading to a larger cohort of children requiring vaccinations. This demographic shift presents a substantial opportunity for vaccine manufacturers to expand their reach. Additionally, as these regions develop economically, there is a growing emphasis on healthcare infrastructure, which supports vaccination programs. The combination of population growth and improved healthcare access is likely to drive significant demand for pediatric vaccines, further solidifying the market's expansion.

    Increased Awareness of Vaccine Benefits

    Public awareness regarding the benefits of vaccination is a driving force in the Global Pediatric Vaccines Market Industry. Campaigns aimed at educating parents about the importance of immunization have led to higher vaccination rates. For instance, initiatives by health organizations highlight the role of vaccines in preventing serious diseases and promoting overall child health. This increased awareness is particularly crucial in combating vaccine hesitancy, which can hinder immunization efforts. As more parents recognize the value of vaccines, the demand for pediatric vaccines is expected to rise, contributing to the market's growth trajectory.

    Rising Incidence of Infectious Diseases

    The Global Pediatric Vaccines Market Industry is experiencing growth due to the increasing incidence of infectious diseases among children. For instance, diseases such as measles and pertussis have seen a resurgence in various regions, prompting health authorities to advocate for vaccination. This trend is particularly evident in low- and middle-income countries, where vaccination rates have historically lagged. The World Health Organization emphasizes the importance of immunization in preventing outbreaks, which further drives demand for pediatric vaccines. As a result, the market is projected to reach 19.2 USD Billion in 2024, reflecting a heightened focus on child health and disease prevention.

    Technological Advancements in Vaccine Development

    Technological advancements are transforming the Global Pediatric Vaccines Market Industry by enabling the development of more effective and safer vaccines. Innovations such as mRNA technology and nanoparticle-based vaccines are being explored to enhance immunogenicity and reduce side effects. These advancements not only improve vaccine efficacy but also expedite the development process, allowing for quicker responses to emerging infectious diseases. As a result, the market is likely to benefit from increased investment in research and development, which could lead to a compound annual growth rate of 9.9% from 2025 to 2035, reflecting the potential for significant growth in the coming years.

    Market Segment Insights

    Pediatric Vaccines Market Vaccine Type Insights   

    The Pediatric Vaccines Market is an essential component of healthcare, focusing on the immunization of children against various infectious diseases. In 2023, the overall market is valued at 38.39 USD Billion, highlighting its significant size and importance within the global health landscape. The market is segmented into various vaccine types, including Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, and Conjugate Vaccines, each playing a critical role in disease prevention for pediatric populations.

    Live Attenuated Vaccines are leading the segment with a valuation of 10.0 USD Billion in 2023, and their growth trajectory is expected to amplify to 20.0 USD Billion by 2032.

    This category is essential as it provides long-term immunity and is effective in generating a robust immune response, making it a preferred choice for routine immunizations worldwide. Following closely, the Inactivated Vaccines segment holds a valuation of 12.0 USD Billion in 2023, with projections to reach 23.0 USD Billion by 2032. Inactivated Vaccines are widely utilized due to their safety profile, which allows for the immunization of vulnerable populations, such as infants and those with immune system disorders.

    Additionally, Subunit Vaccines, valued at 8.0 USD Billion currently and projected to rise to 15.0 USD Billion by 2032, offer targeted immunity with less risk of adverse reactions, thus presenting a favorable option in pediatric vaccination programs.

    Lastly, Conjugate Vaccines, with a valuation of 8.39 USD Billion in 2023 and expected to grow to 17.0 USD Billion by 2032, play a significant role in enhancing immune responses against encapsulated bacteria, thereby preventing serious infections in children. This diversification in Vaccine Types within the Pediatric Vaccines Market indicates the ongoing innovation and adaptation in vaccine development to meet the evolving health needs of children. As demand for vaccine-preventable disease control continues to rise, segments like Live Attenuated and Inactivated Vaccines are anticipated to dominate due to their established efficacy and broad application in routine immunization schedules.

    Pediatric Vaccines Market Administration Route Insights   

    The Pediatric Vaccines Market's Administration Route segment plays a crucial role in determining how vaccines are delivered to children, which impacts their effectiveness and acceptance. In 2023, the overall market is valued at 38.39 USD Billion, and the importance of various administration methods is seen in their widespread usage. Intramuscular and subcutaneous routes are particularly significant due to their established efficacy in delivering vaccines systematically. Meanwhile, oral and nasal administrations offer advantages in ease of administration and improved acceptance among children, making them essential for certain vaccine types.

    The nuanced preferences for different routes highlight the diverse strategies adopted in immunizing the pediatric population effectively. As the market grows, innovations and developments within these administration methods will likely drive further demand, aligning with an overall growth trajectory within the Pediatric Vaccines Market revenue. The Pediatric Vaccines Market statistics indicate evolving trends with the potential for expanded coverage through these varied routes, adjusted according to regional healthcare practices and advancements.

    Overall, these dynamics underscore the importance of careful consideration in Pediatric Vaccines Market segmentation to address both challenges and opportunities in public health vaccination strategies.

    Pediatric Vaccines Market Age Group Insights   

    The Pediatric Vaccines Market is witnessing substantial growth across various age groups, driven by the increasing awareness of disease prevention and vaccination programs. The overall market is expected to be valued at 38.39 USD Billion in 2023, reflecting a significant commitment to enhancing public health. Within this segment, Infants represent a crucial demographic, as they face the highest risk of vaccine-preventable diseases and require a series of immunizations to build immunity. Children also play a vital role, as routine immunizations are essential for school attendance and overall health.

    Moreover, Adolescents are increasingly recognized for their need for vaccines, particularly those that protect against diseases like HPV and meningitis. This group is becoming more significant in the Pediatric Vaccines Market, as targeted vaccination campaigns aim to address public health challenges related to this age cohort. The trends toward comprehensive vaccination schedules and advancing vaccine technologies contribute to market growth, while challenges such as vaccine hesitancy present potential barriers. 

    Overall, the segmentation of the Pediatric Vaccines Market by age group underscores the importance of tailored immunization strategies to meet the diverse needs of young populations, with relevant statistics highlighting its ongoing evolution and significance in the healthcare industry.

    Pediatric Vaccines Market Disease Target Insights   

    The Pediatric Vaccines Market, valued at 38.39 billion USD in 2023, comprises a diverse array of disease targets, including viral, bacterial, and parasitic infections. This market showcases significant growth potential, with forecasts estimating its value to reach 75.0 billion USD by 2032. Viral infections remain a major focal point, predominantly due to ongoing public health campaigns aimed at combating diseases such as measles and rotavirus, which burden healthcare systems worldwide. Bacterial infections are equally crucial, as vaccines play a vital role in preventing conditions like whooping cough and meningitis, which are critical for child health.

    Parasitic infections, while less pronounced, represent an important area due to the global burden of diseases such as malaria, particularly in endemic regions. The Pediatric Vaccines Market segmentation highlights a comprehensive response to various health challenges, underscoring the importance of vaccines in reducing disease prevalence and improving public health outcomes. 

    Growth drivers include increasing immunization coverage rates, advancements in vaccine technology, and heightened awareness of vaccine benefits, contributing to a dynamic landscape within the Pediatric Vaccines Market industry.However, challenges such as vaccine hesitancy and access disparities are present, providing opportunities for enhanced education and outreach initiatives.

    Get more detailed insights about Pediatric Vaccines Market Research Report - Forecast till 2034

    Regional Insights

    The Pediatric Vaccines Market is projected to reach a valuation of 38.39 USD Billion in 2023, with significant growth anticipated across various regions. North America dominates the landscape, holding a substantial market share with a value of 16.0 USD Billion in 2023 and expected to grow to 30.0 USD Billion by 2032, driven by robust healthcare infrastructure and high vaccination rates. In Europe, the market is valued at 10.0 USD Billion in 2023, with projections of 20.0 USD Billion by 2032, supported by government initiatives and awareness campaigns promoting childhood immunization.

    The APAC region, with a valuation of 8.0 USD Billion in 2023, is also gaining traction, as increasing healthcare expenditure and rising awareness about pediatric health bolster market growth, edexpected to reach 15.0 USD Billion by 2032. In South America, the market reflects a value of 2.5 USD Billion in 2023, anticipated to increase to 5.0 USD Billion, as there is growing emphasis on vaccination programs amid economic development.

    Meanwhile, the MEA region, though smaller with a valuation of 1.89 USD Billion in 2023, is witnessing growth opportunities as efforts to improve healthcare access and vaccination coverage intensify, projecting growth to 5.0 USD Billion by 2032.

    Overall, the Pediatric Vaccines Market showcases diverse dynamics across regions, influenced by healthcare policies, economic factors, and public health initiatives.

    Source Primary Research, Secondary Research, Market Research Future Database and Analyst Review

    Key Players and Competitive Insights

    The Pediatric Vaccines Market is characterized by a dynamic and rapidly evolving landscape, which features a growing emphasis on the importance of immunization in child health management. As countries increase healthcare access and prioritize childhood vaccination programs, the market is set to expand significantly. Competitive insights reveal that companies involved in this sector are focusing on innovative vaccine development, strategic partnerships, and collaborations to enhance their market presence. The evolving regulatory environment and advancements in vaccine technology are also driving competition as firms strive to create more effective and safer vaccines tailored specifically for pediatric populations. 

    Moreover, the global pandemic has amplified the focus on vaccine development, undoubtedly influencing the strategies and investment decisions of key players in this market.BristolMyers Squibb stands out in the Pediatric Vaccines Market due to its strong commitment to research and development, which allows it to innovate and enhance the pediatric vaccine portfolio. The company benefits from a robust pipeline of vaccine candidates that address critical health needs in children, combining extensive scientific expertise with operational proficiency to bring these products to market. 

    BristolMyers Squibb’s strength lies in its ability to leverage strategic partnerships and collaborations with academic institutions and research organizations, facilitating faster development and distribution of vaccines. Furthermore, the company's established global presence, enhanced by its reputation for quality and safety, positions it favorably among healthcare providers and public health entities, thereby boosting its competitive edge in catering to the pediatric population.Sanofi is a prominent player in the Pediatric Vaccines Market, offering a diverse range of immunization solutions designed specifically for children. 

    The company has a well-established reputation for the efficacy and safety of its vaccines, which has been built over decades of experience in the industry. Sanofi's extensive research capabilities enable it to stay at the forefront of vaccine innovation, allowing for the rapid development of new products. Additionally, the company’s international reach and strong distribution network enhance its ability to deliver pediatric vaccines to various markets, ensuring consistent availability in both well-developed and emerging economies.

    Sanofi's dedication to public health initiatives further reinforces its market position, as it actively engages in educational programs to promote vaccine awareness and uptake among parents and healthcare professionals.

    Key Companies in the Pediatric Vaccines Market market include

    Industry Developments

    • Q2 2024: Sanofi, BioNTech to collaborate on mRNA-based pediatric vaccine development Sanofi and BioNTech announced a strategic partnership to co-develop and commercialize mRNA-based vaccines targeting pediatric infectious diseases, aiming to accelerate innovation in the pediatric vaccine sector.
    • Q2 2024: Pfizer Receives FDA Approval for New Pediatric Pneumococcal Conjugate Vaccine Pfizer announced that the U.S. Food and Drug Administration approved its new 20-valent pneumococcal conjugate vaccine for use in children, expanding protection against additional strains of the bacteria.
    • Q3 2024: Moderna launches clinical trial for next-generation pediatric RSV vaccine Moderna initiated a Phase 2/3 clinical trial for its next-generation mRNA-based RSV vaccine in pediatric populations, marking a significant step in expanding its vaccine portfolio for children.
    • Q3 2024: GSK opens new pediatric vaccine manufacturing facility in Belgium GSK inaugurated a state-of-the-art manufacturing facility in Belgium dedicated to the production of pediatric vaccines, aiming to increase global supply and support future vaccine launches.
    • Q4 2024: Sanofi and UNICEF sign supply agreement for pediatric combination vaccines Sanofi entered into a multi-year supply agreement with UNICEF to provide combination vaccines for pediatric immunization programs in low- and middle-income countries.
    • Q4 2024: Serum Institute of India receives WHO prequalification for new pediatric hexavalent vaccine The Serum Institute of India announced that its new hexavalent pediatric vaccine received WHO prequalification, enabling its distribution through global immunization initiatives.
    • Q1 2025: Pfizer appoints new Global Head of Pediatric Vaccines Pfizer named Dr. Maria Lopez as the new Global Head of Pediatric Vaccines, reflecting the company's commitment to leadership in the pediatric immunization sector.
    • Q1 2025: Bharat Biotech secures funding to expand pediatric vaccine R&D Bharat Biotech raised $120 million in a new funding round to accelerate research and development of next-generation pediatric vaccines, with a focus on affordable solutions for emerging markets.
    • Q2 2025: Merck & Co. acquires pediatric vaccine startup VaxGenix Merck & Co. completed the acquisition of VaxGenix, a biotech startup specializing in novel pediatric vaccine platforms, to strengthen its pipeline and innovation capabilities.
    • Q2 2025: GSK and Takeda announce partnership to co-develop pediatric dengue vaccine GSK and Takeda entered a partnership to jointly develop and commercialize a new pediatric dengue vaccine, targeting regions with high disease burden.
    • Q2 2025: Sanofi launches new pediatric meningococcal vaccine in Europe Sanofi announced the commercial launch of its new pediatric meningococcal vaccine in several European countries, expanding its portfolio of childhood immunizations.
    • Q3 2025: Indian Immunologicals opens new pediatric vaccine R&D center in Hyderabad Indian Immunologicals inaugurated a new research and development center in Hyderabad focused on the discovery and development of innovative pediatric vaccines.

    Future Outlook

    Pediatric Vaccines Market Future Outlook

    The Pediatric Vaccines Market is projected to grow at a 9.9% CAGR from 2024 to 2035, driven by increasing vaccination awareness, technological advancements, and government initiatives.

    New opportunities lie in:

    • Develop combination vaccines to enhance immunization rates and reduce administration costs.
    • Leverage digital health technologies for vaccine tracking and patient engagement.
    • Expand into emerging markets with tailored vaccination programs and partnerships.

    By 2035, the Pediatric Vaccines Market is expected to achieve substantial growth, reflecting enhanced global health outcomes.

    Market Segmentation

    Pediatric Vaccines Market Regional Outlook

    • North America
    • Europe
    • South America
    • Asia Pacific
    • Middle East and Africa

    Pediatric Vaccines Market Age Group Outlook

    • Infants
    • Children
    • Adolescents

    Pediatric Vaccines Market Vaccine Type Outlook

    • Live Attenuated Vaccines
    • Inactivated Vaccines
    • Subunit Vaccines
    • Conjugate Vaccines

    Pediatric Vaccines Market Disease Target Outlook

    • Viral Infections
    • Bacterial Infections
    • Parasitic Infections

    Pediatric Vaccines Market Administration Route Outlook

    • Intramuscular
    • Subcutaneous
    • Oral
    • Nasal

    Report Scope

    Report Attribute/Metric Details
    Market Size 2024   19.20 (USD Billion)
    Market Size 2025   21.10 (USD Billion)
    Market Size 2034   49.36 (USD Billion)
    Compound Annual Growth Rate (CAGR)    9.90 % (2025–2034)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2024
    Market Forecast Period 2025 - 2034
    Historical Data 2020 - 2024
    Market Forecast Units USD Billion
    Key Companies Profiled BristolMyers Squibb, Sanofi, Emergent BioSolutions, HoffmannLa Roche, United Therapeutics, AbbVie, VBI Vaccines, Serum Institute of India, GlaxoSmithKline, Johnson  and  Johnson, Valneva, Pfizer, Inovio Pharmaceuticals, Merck  and  Co, Novartis
    Segments Covered Vaccine Type, Administration Route, Age Group, Disease Target, Regional
    Key Market Opportunities Increased vaccination awareness, Emerging markets expansion, Technological advancements in vaccine development, Rising prevalence of infectious diseases, Government initiatives for immunization programs
    Key Market Dynamics Increasing vaccine-preventable diseases, Growing public health initiatives, Rising awareness of immunization, Technological advancements in vaccine development, Stringent regulatory frameworks
    Countries Covered North America, Europe, APAC, South America, MEA

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What is the expected market size of the Pediatric Vaccines Market by 2032?

    The Pediatric Vaccines Market is expected to reach a valuation of 49.36 USD Billion by 2034

    What is the expected CAGR for the Pediatric Vaccines Market from 2025 to 2034?

    The expected CAGR for the Pediatric Vaccines Market from 2025 to 2034 is 9.90 %.

    Which region is projected to have the largest market share in the Pediatric Vaccines Market by 2032?

    North America is projected to have the largest market share, valued at 30.0 USD Billion by 2032.

    What is the market value of Inactivated Vaccines in 2032?

    The market value of Inactivated Vaccines is expected to be 23.0 USD Billion by 2032.

    Who are the key players in the Pediatric Vaccines Market?

    Key players include BristolMyers Squibb, Sanofi, Emergent BioSolutions, and GlaxoSmithKline, among others.

    What is the expected market size for Live Attenuated Vaccines by 2032?

    The market size for Live Attenuated Vaccines is expected to reach 20.0 USD Billion by 2032.

    How much is the Conjugate Vaccines segment expected to grow by 2032?

    The Conjugate Vaccines segment is expected to grow to 17.0 USD Billion by 2032.

    What is the projected market value for the APAC region in 2032?

    The projected market value for the APAC region is expected to be 15.0 USD Billion by 2032.

    What challenges may impact the growth of the Pediatric Vaccines Market?

    Challenges may include regulatory hurdles and varying access to healthcare, impacting market growth.

    What is the forecasted market value for the South American region by 2032?

    The forecasted market value for the South American region is expected to be 5.0 USD Billion by 2032.

    Pediatric Vaccines Market Research Report - Forecast till 2034 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Stories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study
    Chemicals and Materials